Atlas Trials

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Clinical trial NCT06263959 · RECRUITING

Trial details

NCT number
NCT06263959
Sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Hepatitis B
Start date
2023-12-26
Primary completion
2025-04-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.